Stefan K James

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi request reprint Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial
    Stefan James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Am J Med 115:178-84. 2003
  2. ncbi request reprint Diagnostic applications of natriuretic peptides in ischemic heart disease
    Bertil Lindahl
    University Hospital of Uppsala, Uppsala, Sweden
    Heart Fail Clin 2:311-21. 2006
  3. ncbi request reprint An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease
    Stefan K James
    The Research Group of Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Am Heart J 149:619-26. 2005
  4. ncbi request reprint Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy)
    Stefan K James
    Department of Medical Sciences and Cardiology, Academic Hospital, Uppsala, Sweden
    Am J Cardiol 97:167-72. 2006
  5. doi request reprint Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden
    Stefan K James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    N Engl J Med 360:1933-45. 2009
  6. ncbi request reprint Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin
    Stefan James
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Ups J Med Sci 109:71-122. 2004
  7. ncbi request reprint [Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice]
    Stefan James
    Kardiologiska kliniken, Akademiska sjukhuset, Uppsala
    Lakartidningen 101:1514-9, 1521-2. 2004
  8. ncbi request reprint Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy
    Stefan K James
    Department of Medical Sciences, Cardiology, Thoraxcenter, Academic Hospital, Uppsala, Sweden
    Am Heart J 147:267-74. 2004
  9. ncbi request reprint Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy
    Stefan K James
    Uppsala Clinical Research Center, Uppsala, Sweden
    J Am Coll Cardiol 48:1146-54. 2006
  10. ncbi request reprint N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (
    Stefan K James
    Department of Medical Sciences, Cardiology, University of Uppsala, Uppsala, Sweden
    Circulation 108:275-81. 2003

Detail Information

Publications47

  1. ncbi request reprint Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial
    Stefan James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Am J Med 115:178-84. 2003
    ..However, the appropriate cutoff for identifying patients with the acute coronary syndrome who are at low risk of subsequent mortality has not been established...
  2. ncbi request reprint Diagnostic applications of natriuretic peptides in ischemic heart disease
    Bertil Lindahl
    University Hospital of Uppsala, Uppsala, Sweden
    Heart Fail Clin 2:311-21. 2006
  3. ncbi request reprint An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease
    Stefan K James
    The Research Group of Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Am Heart J 149:619-26. 2005
    ..Inflammation plays an important role in unstable coronary artery disease (CAD). We assessed the kinetics of inflammatory markers from symptom onset in patients with unstable CAD and their relation to myocardial damage...
  4. ncbi request reprint Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy)
    Stefan K James
    Department of Medical Sciences and Cardiology, Academic Hospital, Uppsala, Sweden
    Am J Cardiol 97:167-72. 2006
    ..Despite a larger proportion of ST depression and increased levels of NT-pro-BNP and interleukin-6 at admission, these factors provide independent prognostic information that may improve risk stratification and guidance of treatment...
  5. doi request reprint Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden
    Stefan K James
    Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    N Engl J Med 360:1933-45. 2009
    ..The long-term safety and efficacy of drug-eluting coronary stents have been questioned...
  6. ncbi request reprint Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin
    Stefan James
    Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden
    Ups J Med Sci 109:71-122. 2004
    ..Any detectable elevation of TnT and reduced creatinine clearance, but neither elevation of CRP nor NT-proBNP, were also independently associated to a raised risk of subsequent myocardial infarction...
  7. ncbi request reprint [Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice]
    Stefan James
    Kardiologiska kliniken, Akademiska sjukhuset, Uppsala
    Lakartidningen 101:1514-9, 1521-2. 2004
    ....
  8. ncbi request reprint Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy
    Stefan K James
    Department of Medical Sciences, Cardiology, Thoraxcenter, Academic Hospital, Uppsala, Sweden
    Am Heart J 147:267-74. 2004
    ..In addition to platelet inhibition, recent evidence suggests that the glycoprotein IIb/IIIa receptor inhibitor abciximab attenuates inflammation and coagulation activity...
  9. ncbi request reprint Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy
    Stefan K James
    Uppsala Clinical Research Center, Uppsala, Sweden
    J Am Coll Cardiol 48:1146-54. 2006
    ..This study was designed to evaluate biomarkers for selection of patients with non-ST-segment elevation acute coronary syndromes (ACS) that derive mortality benefit from revascularization...
  10. ncbi request reprint N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (
    Stefan K James
    Department of Medical Sciences, Cardiology, University of Uppsala, Uppsala, Sweden
    Circulation 108:275-81. 2003
    ....
  11. ncbi request reprint A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes
    Stefan K James
    Department of Medical Sciences, Cardiology, Uppsala, Sweden
    Int J Cardiol 93:113-20. 2004
    ..Troponin is a specific marker of myocardial damage. For early prediction of coronary events in patients with suspicion of acute coronary syndromes the assay also needs to be highly sensitive...
  12. doi request reprint Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study
    Axel Akerblom
    Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Clin Chem 58:190-9. 2012
    ....
  13. ncbi request reprint Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy
    Stefan K James
    Department of Medical Sciences Cardiology, Thoraxcenter, Academic Hospital, 751 85 Uppsala, Sweden
    J Am Coll Cardiol 41:916-24. 2003
    ..We sought to evaluate C-reactive protein (CRP) and troponin T (TnT) as predictors of risk of the individual end points of mortality and myocardial infarction (MI) in a large cohort of patients with acute coronary syndrome (ACS)...
  14. doi request reprint Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry)
    Ole Frobert
    Department of Cardiology, Orebro University Hospital, Orebro, Sweden
    J Am Coll Cardiol 53:1660-7. 2009
    ..Our aim was to evaluate restenosis rate of drug-eluting stents (DES) in patients with and without diabetes mellitus (DM) in a real-world setting...
  15. doi request reprint Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study
    Axel Akerblom
    Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Am Heart J 164:728-34. 2012
    ....
  16. doi request reprint Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
    Ulf Stenestrand
    Department of Cardiology, University Hospital, 581 85 Linkoping, Sweden
    Eur Heart J 31:177-86. 2010
    ..Patients with diabetes mellitus have more extensive coronary artery disease, more disease progression, and restenosis. The use of drug-eluting stents (DES) in these patients is widespread, despite uncertain long-term safety and efficacy...
  17. doi request reprint Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)
    Axel Akerblom
    Department of Cardiology, UppsalaClinical Research Center, Uppsala University, Uppsala, Sweden
    J Am Coll Cardiol 56:470-5. 2010
    ..The aim of this study was to test the noninferiority of eptifibatide relative to abciximab in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI)...
  18. ncbi request reprint Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)
    Marieke L Fokkema
    Thoraxcenter, Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Am Coll Cardiol 61:1222-30. 2013
    ..The aim of this study was to describe the characteristics and outcome of all consecutive patients treated with percutaneous coronary intervention (PCI) in an unselected nationwide cohort over the past 2 decades...
  19. ncbi request reprint Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden
    Bo Lagerqvist
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    N Engl J Med 356:1009-19. 2007
    ..Recent reports have indicated that there may be an increased risk of late stent thrombosis with the use of drug-eluting stents, as compared with bare-metal stents...
  20. doi request reprint Thrombus aspiration during ST-segment elevation myocardial infarction
    Ole Frobert
    From the Department of Cardiology, Orebro University Hospital, Örebro O F, F C, Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Uppsala B L, O O, S K J, Department of Cardiology, Lund University Hospital, Lund G K O, D E, J H, Department of Cardiology, Sahlgrenska University Hospital, Gothenburg E O, O A, Department of Cardiology, Karolinska Institutet, Sodersjukhuset M A, and Cardiology Unit, Department of Medicine, Karolinska University Hospital U J, Stockholm, Department of Cardiology, Karlstad Hospital, Karlstad M D, Department of Cardiology, Gavle Hospital, Gävle L H, PCI unit, Sunderby Hospital, Sunderby A C J, Department of Cardiology, Västerås Hospital, Västerås A K, Department of Cardiology, Heart Center
    N Engl J Med 369:1587-97. 2013
    ..We aimed to evaluate whether thrombus aspiration reduces mortality...
  21. doi request reprint Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry
    Bo Lagerqvist
    Uppsala Clinical Research Centre, Uppsala University Hospital, Uppsala, Sweden
    Circ Cardiovasc Interv 2:401-8. 2009
    ..The objective was to evaluate the role of risk factors and stent type for stent thrombosis (ST) using a large real world registry...
  22. doi request reprint Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study
    Axel Akerblom
    Department of Medical Sciences, Cardiology, Uppsala University, Uppsala Sweden
    Clin Chem 59:1369-75. 2013
    ..We evaluated 2 different cystatin C assays, alone or combined with creatinine, in patients with acute coronary syndrome...
  23. pmc Effect of stent inflation pressure and post-dilatation on the outcome of coronary artery intervention. A report of more than 90,000 stent implantations
    Ole Frobert
    Department of Cardiology, Orebro University Hospital, Orebro, Sweden
    PLoS ONE 8:e56348. 2013
    ..Using comprehensive registry data our aim was to evaluate how stent inflation pressure influences restenosis, stent thrombosis and death following PCI...
  24. doi request reprint Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition a
    Lars Wallentin
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden L W, D L, L W, C H, S K J Department of Medical Sciences, Clinical Chemistry and Uppsala Clinical Research Center Uppsala University, Uppsala, Sweden A S Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, Academic Health Center, Cincinnati, OH R C B Department of Medicine, Stanford University, Stanford, CA R A H, K W M TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA C P C Department of Cardiology, Medisch Centrum Alkmaar, Alkmaar, Netherlands J H C AstraZeneca Research and Development, Molndal, Sweden A H Medizinische Klinik, Universitatsklinikum Heidelberg, Heidelberg, Germany E G, H A K Medical Department, Hospital Unit West, Herning Holstbro, Denmark S H INSERM Unité 698, Paris, Department of Biochemistry
    Circulation 129:293-303. 2014
    ....
  25. doi request reprint Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome
    Kai M Eggers
    Dept of Medical Sciences, Cardiology, Uppsala University, 75237 Uppsala, Sweden Electronic address
    Clin Biochem 46:1655-9. 2013
    ..The aim of the present analysis was to investigate the implications of PTX3 levels in a fairly large sample of NSTE-ACS patients and in comparison to levels of C-reactive protein (CRP)...
  26. doi request reprint Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack
    Stefan K James
    Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    Circulation 125:2914-21. 2012
    ..Patients with acute coronary syndromes and history of stroke or transient ischemic attack (TIA) have an increased rate of recurrent cardiac events and intracranial hemorrhages...
  27. doi request reprint Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and
    Ole Frobert
    Department of Cardiology, Orebro University Hospital, Orebro, Sweden
    Am Heart J 160:1042-8. 2010
    ..Thrombus aspiration is widely used in clinical practice and is recommended by international guidelines despite limited evidence...
  28. doi request reprint Long-term safety and efficacy of drug-eluting and bare metal stents in saphenous vein grafts
    Ole Frobert
    Department of Cardiology, Orebro University Hospital, Sweden
    Am Heart J 164:87-93. 2012
    ..Long-term safety and efficacy data of drug-eluting stents (DESs) in saphenous vein grafts (SVGs) are lacking. This study sought to compare the clinical outcomes of DES versus bare metal stents (BMS) in SVGs...
  29. ncbi request reprint Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients
    Jonas Oldgren
    Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
    Eur Heart J 28:699-704. 2007
    ....
  30. ncbi request reprint NT-proBNP in unstable coronary artery disease--experiences from the FAST, GUSTO IV and FRISC II trials
    Tomas Jernberg
    Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, University Hospital, Uppsala 751 85, Sweden
    Eur J Heart Fail 6:319-25. 2004
    ..e. unstable angina or non-ST-elevation myocardial infarction. This article focuses on the emerging role of N-terminal pro brain natriuretic peptide (NT-proBNP) and the results from the FAST, GUSTO IV and FRISC II trials...
  31. doi request reprint Clinical performance of two highly sensitive cardiac troponin I assays
    Per Venge
    Department of Medical Sciences, Clinical Chemistry, University of Uppsala
    Clin Chem 55:109-16. 2009
    ..The aim of this study was to compare the clinical performance of 2 sensitive cTnI assays with 10% CV imprecision below the 99th percentile upper reference limit...
  32. ncbi request reprint Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome
    Tomas Jernberg
    Department of Medical Sciences, Cardiology, Uppsala Research Center, University Hospital, 751 85 Uppsala, Sweden
    Circulation 110:2342-8. 2004
    ..Cystatin C is a new and better marker of renal function than creatinine. The aim was therefore to evaluate the prognostic value of cystatin C in this population...
  33. doi request reprint Proximal coronary artery intervention: stent thrombosis, restenosis and death
    Fredrik Calais
    Department of Cardiology, Orebro University Hospital, Orebro, Sweden
    Int J Cardiol 170:227-32. 2013
    ....
  34. doi request reprint ST2 and mortality in non-ST-segment elevation acute coronary syndrome
    Kai M Eggers
    Department of Medical Sciences, Uppsala University, Sweden
    Am Heart J 159:788-94. 2010
    ....
  35. ncbi request reprint The antibody configurations of cardiac troponin I assays may determine their clinical performance
    Stefan James
    Department of Medical Sciences, Cardiology, Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden
    Clin Chem 52:832-7. 2006
    ..The approach has been adopted by the new cTnI assay from Abbott Diagnostics. The aim of our study was to investigate whether this approach affects the clinical performance of cTnI assays...
  36. doi request reprint Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia
    Per Venge
    Department of Medical Sciences, University of Uppsala, Sweden
    J Am Coll Cardiol 54:1165-72. 2009
    ..This study sought to evaluate the analytical and clinical performance of the novel hypersensitive cardiac troponin I (cTnI) prototype assay from Beckman Coulter (Fullerton, California)...
  37. doi request reprint Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR])
    Peter Damman
    Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands Electronic address
    Am J Cardiol 113:64-9. 2014
    ..Mortality and bleeding rates were lower with prasugrel than clopidogrel, probably because of patient selection. ..
  38. doi request reprint Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department Medical Sciences and Cardiology, Uppsala University, Sweden
    Am Heart J 157:562.e1-9. 2009
    ..These tests need to be evaluated in comparison to reference measurements of P2Y(12) function during different thienopyridine treatments...
  39. doi request reprint The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes
    Bertil Lindahl
    Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, University of Uppsala, Uppsala, Sweden
    Am Heart J 160:224-9. 2010
    ..However, how the hs-cTnT assay compares with the old cTnT assay for risk assessment in ACS is still unknown...
  40. ncbi request reprint Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
    Oscar O Braun
    Department of Medical Sciences, Clinical Chemistry, Akademiska Hospital, Uppsala, Sweden
    Thromb Haemost 100:626-33. 2008
    ..Attenuated platelet aggregation and reduced expression of platelet pro-coagulant and pro-inflammatory markers with prasugrel suggest the potential to reduce cardiovascular events both in the acute setting and in long-term treatment...
  41. pmc Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan K James
    Uppsala Clinical Research Center, Uppsala University, Sweden
    BMJ 342:d3527. 2011
    ..To evaluate efficacy and safety outcomes in patients in the PLATelet inhibition and patient Outcomes (PLATO) trial who at randomisation were planned for a non-invasive treatment strategy...
  42. doi request reprint Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
    ..Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel...
  43. doi request reprint Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Sweden
    Am Heart J 157:599-605. 2009
    ....
  44. ncbi request reprint Natriuretic peptides in unstable coronary artery disease
    Tomas Jernberg
    Department of Medical Sciences, Cardiology and Uppsala Research Center, Sweden
    Eur Heart J 25:1486-93. 2004
    ..Before a routine use of BNP or NT-proBNP in unstable CAD can be recommended, the cost-effectiveness of adding these new markers to the currently routine markers and their impact on selection of treatment needs further evaluation...
  45. ncbi request reprint Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    Lars Wallentin
    Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 29:21-30. 2008
    ..P2Y(12) receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were investigated in patients with stable coronary artery disease...
  46. pmc Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Eur Heart J 30:1744-52. 2009
    ..We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel...
  47. doi request reprint Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
    David Erlinge
    Department of Cardiology, Lund University, Lund, Sweden
    J Am Coll Cardiol 52:1968-77. 2008
    ..We evaluated the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary artery disease patients with and without diabetes...